<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-162630</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Fernández-Martínez, C</dc:creator>
<dc:creator>Rodrigo, R</dc:creator>
<dc:creator>Salom, D</dc:creator>
<dc:creator>Hervás, A</dc:creator>
<dc:creator>Navarro-Navarro, A</dc:creator>
<dc:creator>Martínez-Toldos, JJ</dc:creator>
<dc:creator>Udaondo, P</dc:creator>
<dc:creator>Gutiérrez-Arias, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(5): 245-246, mayo 2017.</dc:source>
<dc:identifier>ibc-162630</dc:identifier>
<dc:title xml:lang="es">Análisis del DRCR Network sobre coste-efectividad de aflibercept, bevacizumab y ranibizumab para el tratamiento de edema macular diabético y su aplicación en España</dc:title>
<dc:subject>^d1716^s22074</dc:subject>
<dc:subject>^d3954^s22057</dc:subject>
<dc:subject>^d29625</dc:subject>
<dc:subject>^d29638</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d50303</dc:subject>
<dc:subject>^d28131^s22057</dc:subject>
<dc:subject>^d55979^s22073</dc:subject>
<dc:subject>^d55974^s22073</dc:subject>
<dc:subject>^d54215^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201705</dc:date>
</metadata>
</record>
</ibecs-document>
